Genfit To Pick Up Second Liver Failure Candidate In €40m Versantis Buyout

 
• By Joseph Haas

Focused on rare liver diseases such as acute-on-chronic liver failure following its 2020 disappointment in NASH, Genfit looks to become sector leader in ACLF and other indications such as hepatic encephalopathy.

Business deal (Genfit/Versantis)
In Genfit's third deal since December, it adds second ACLF candidate • Source: Shutterstock

More from Deals

More from Business